EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Catching our breath: development of interventions and therapies for respiratory syncytial virus

Asha Maria Mathew iD, Grace Neilsen iD, Shuiyun Lan iD, Savannah Leanne Shooter, Jeffrey Shi Jie Zheng iD, Jeremy Estes, Dongdong Cao iD, Raymond F Schinazi iD, Uma S Singh iD, Bo Liang iD, Sujin Lee iD, Stefan G Sarafianos iD

Microbiology and Molecular Biology Reviews · 25.06.2026 · 90 (2)

DOI: 10.1128/mmbr.00431-25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Microbiology and Molecular Biology Reviews, erschienen am 25.06.2026. Verfasst von Asha Maria Mathew und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Geor…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antiviral Agents, Respiratory Syncytial Virus, Human. Die Arbeit nennt 316 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) continues to be a significant global health concern, particularly affecting infants, young children, and older adults. Although the virus was discovered decades ago, a complete cure remains elusive. RSV is a leading cause of lower respiratory tract infections, contributing to significant illness and mortality around the world. Recent scientific advances have brought promising developments in the fight against RSV. Progress in vaccine technology has led to the approval and distribution of preventative vaccines, particularly for high-risk groups. Monoclonal antibodies, designed to target and neutralize the virus, are used both to prevent and treat infections. Antiviral treatments, though still limited, are also showing potential in reducing disease severity and duration. Advanced animal and controlled human infection models have bolstered preclinical and clinical research, allowing for the testing and refinement of therapeutic candidates in more physiologically relevant systems. These models are playing a crucial role in understanding disease mechanisms and evaluating the efficacy of new interventions. As the field rapidly evolves, it is essential to pause and assess our current standing in the fight against RSV. In many ways, we are finally catching our breath —equipped with better tools and a deeper understanding, yet still facing the challenges of a persistent and complex virus. Continued innovation, investment, and global collaboration will be essential to translate these developments into widespread therapy for those most vulnerable to RSV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsAntiviral AgentsRespiratory Syncytial Virus, HumanHumansAnimalsRespiratory Syncytial Virus VaccinesDisease Models, AnimalAntibodies, Monoclonal

Stichwörter der Autor:innen

antiviralscontrolled human infection modelmonoclonal antibodiespreclinical animal modelsrespiratory syncytial virusvaccines

Substanzen

Antiviral AgentsRespiratory Syncytial Virus VaccinesAntibodies, Monoclonal

Autor:innen und Institutionen

  • Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Innovations in Drug Discovery (IDD) Program, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, Georgia, USA.
  • Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA.

ORCID-Profile: Asha Maria Mathew, Grace Neilsen, Shuiyun Lan, Jeffrey Shi Jie Zheng, Dongdong Cao, Raymond F Schinazi, Uma S Singh, Bo Liang, Sujin Lee, Stefan G Sarafianos

Förderung

  • NIAID NIH HHS
  • NIGMS NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • University of Georgia Faculty Seed Fund
  • Vernagen
  • Nahmias-Schinazi Chair
  • National Institute of General Medical Sciences

Zitieren

APA

Mathew, A. M., Neilsen, G., Lan, S., Shooter, S. L., Zheng, J. S. J., Estes, J., Cao, D., Schinazi, R. F., Singh, U. S., Liang, B., Lee, S., & Sarafianos, S. G. (2026). Catching our breath: development of interventions and therapies for respiratory syncytial virus. Microbiology and Molecular Biology Reviews, 90(2). https://doi.org/10.1128/mmbr.00431-25

Vancouver

Mathew AM, Neilsen G, Lan S, Shooter SL, Zheng JSJ, Estes J, et al. Catching our breath: development of interventions and therapies for respiratory syncytial virus. Microbiology and Molecular Biology Reviews. 2026;90(2). doi:10.1128/mmbr.00431-25

BibTeX
@article{Mathew2026,
  author = {Mathew, Asha Maria and Neilsen, Grace and Lan, Shuiyun and Shooter, Savannah Leanne and Zheng, Jeffrey Shi Jie and Estes, Jeremy and Cao, Dongdong and Schinazi, Raymond F and Singh, Uma S and Liang, Bo and Lee, Sujin and Sarafianos, Stefan G},
  title = {Catching our breath: development of interventions and therapies for respiratory syncytial virus},
  journal = {Microbiology and Molecular Biology Reviews},
  year = {2026},
  volume = {90},
  number = {2},
  doi = {10.1128/mmbr.00431-25}
}
Kostenlos starten →